Diana N. Ionescu, MD, FRCP(C), FCAP
Medical Director Clinical Trials, BCCA VCC Laboratory
Clinical Professor, Department of Pathology and Laboratory Medicine, UBC
Dr. Ionescu is a graduate of University of Medicine and Pharmacy “Iuliu Hatieganu” in Cluj Napoca, Romania. She completed her postgraduate training in Anatomical and Clinical Pathology at the University of Pittsburgh Medical Center and a Fellowship in Gynecological Pathology at Vancouver General Hospital. She has practiced as a Consultant Pathologist at BC Cancer Agency in Vancouver since 2006. She is currently a Clinical Professor of Pathology at UBC and served as the residency program director for the Anatomic Pathology Residency Program between 2009 – 2017.
Her specific areas of diagnostic expertise are lung, gynecologic and breast pathology. She is an author of over 35 scientific publications and book chapters. She is the author and invited speaker at numerous regional, national and international lectures. Her investigation interests include oncologic pathology and molecular biomarkers, lung cancer and adult health education. She is the Canadian Anatomic and Molecular Pathology (CAMP) course director.
Dr. Ionescu is an enthusiastic advocate of pathologists participating in numerous patient education forums, TV shows, advocacy campaigns, being an Medical Advisor for Lung Cancer Canada and in 2015 appeared before the House of Commons Committee on Health.
Deepu Alex, MD
Department of Pathology and Laboratory Medicine
Dr. Blake Gilks, MD, FRCPC
Professor, University of British Columbia
Co-Founder, Ovarian Cancer Research Program (OVCARE)
Dr. Blake Gilks is Professor in the Dept of Pathology and Laboratory Medicine, at the University of British Columbia, in Vancouver Canada, and does clinical service work in the Division of Anatomic Pathology at Vancouver General Hospital, the site of the largest gynecological oncology program in the province of British Columbia, where he is Regional Medical Director of Laboratories and Head of the Department of Pathology and Laboratory Medicine. He graduated from Dalhousie University medical school in 1982 and did a residency in anatomical pathology at the University of British Columbia, followed by fellowships in gynecological pathology and molecular pathology at Massachusett’s General Hospital and Fox Chase Cancer Center, respectively. Dr. Gilks leads a research program focused on gynecological cancers and is co-founder of the Genetic Pathology Evaluation Centre, a laboratory that uses tissue microarrays of human tumor samples for cancer research, and OvCaRe, a multidisciplinary team studying ovarian cancer. He is also co-founder and co-director of the Canadian Immunohistochemistry Quality Control program, which provides proficiency testing for Canadian diagnostic immunohistochemistry laboratories.
Allen Gown, MD
Medical Director and Chief Pathologist
Director and Chief Pathologist at PhenoPath Laboratories, a Seattle-based national reference immunohistochemistry laboratory founded by Dr. Gown in 1998. He is Clinical Professor of Pathology at the University of British Columbia, Vancouver, and an Affiliate Investigator in the Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle.
Dr. Gown is an internationally recognized authority in the field of diagnostic immunohistochemistry, having published many key papers in this field over the past 20 years. He serves as a member of the Editorial Board for several pathology journals, and regularly gives workshops in diagnostic immunohistochemistry under the auspices of the United States Canadian Academy of Pathology and the American Society of Clinical Pathologists.
Malcolm Hayes, MD, BSc, MB,ChB, LRCP, MRCS, M.Med. Path, FRCPath, FRCPC
Clinical Professor of Pathology and Laboratory Medicine
University of British Columbia
Malcolm Hayes is a pathologist at the BC Cancer Agency (BCCA) in Vancouver. Dr. Hayes has worked at the BCCA since 1993 and has broad expertise in surgical pathology and cytopathology and major interests in breast, skin, gynecological and soft tissue pathology. He is a Clinical Professor of pathology at the University of British Columbia and a Fellow of the Royal College of Pathologist of UK. He has many years of expertise in diagnostic immunohistochemistry based on employment of this technique in the work up of a large volume of challenging consultation cases referred to the BCCA “Primary Unknown” tumour group.
David Huntsman, MD, FRCPC, FCCMG
Dr. Chew Wei Memorial Professor of Gynaecologic Oncology
UBC Professor, Departments of Pathology and Lab Medicine and Obstetrics and Gynaecology
UBC Director of OvCaRe, Vancouver General Hospital, BC Cancer Agency
UBC Distinguished Scientist, Department of Molecular Oncology
BC Cancer Agency Research Centre Canada Research Chair in Molecular and Genomic Pathology
Dr. David Huntsman is the Dr. Chew Wei Memorial Professor of Gynaecologic Oncology, holds the Canada Research Chair (Tier 1) in Molecular and Genomic Pathology, and is a Professor in the Departments of Pathology & Laboratory Medicine and Obstetrics & Gynaecology at The University of British Columbia. He is a Staff Pathologist at the BC Cancer Agency and a Consulting Pathologist at the Vancouver General Hospital.
Dr. Huntsman attended medical school at Memorial University of Newfoundland from 1984-88 and after completing a rotating internship, practiced family medicine in Labrador for two years. Following his experience in family medicine, he entered and completed a pathology residency and trained in clinical molecular genetics at UBC and subsequently studied cancer genetics at Cambridge University, UK.
Dr. Huntsman is a co-founder and Director of BC’s Ovarian Cancer Research (OVCARE) Program, where he leads a multidisciplinary team of over 50 scientists, staff and trainees in the study of ovarian and other gynaecological cancers. He is also co-Director of the Genetic Pathology Evaluation Centre (GPEC) at the Jack Bell Research Centre, VGH and former Medical Director of the Centre for Translational and Applied Genomics (CTAG) at the BCCA.
Dr. Huntsman’s research has led to the development of predictive and prognostic tissue-based cancer biomarkers for ovarian cancer and a wide variety of other tumour types. His team created a blueprint for histotype specific ovarian cancer control and have been leaders in the application of novel genomics technologies to ovarian cancer.
Recently, his team applied next generation sequencing technologies to ovarian cancers and discovered key mutations in granulosa cell tumours, clear cell and endometrioid carcinomas, sertoli-leydig cell tumours of the ovary and small cell carcinomas of the ovary. His team is working to determine the biologic and clinical relevance of these discoveries with a view to developing new treatment, diagnostic and prevention opportunities.
Dr. Huntsman is the recipient of numerous awards including the prestigious William E. Rawls Prize for contributions to advances in cancer control in Canada (2014), the Gerald Award for Translational Research and Pathology from the Memorial Sloan Ketter Cancer Center (2016), the Karen Campbell National Award for Excellence in Ovarian Cancer Research (Feb 2012), the Killam Research Prize and Overall Excellence Senior Faculty Award from the UBC Faculty of Medicine (2012), and the inaugural Virginia Greene leadership award for ovarian cancer research and advocacy (Sept 2011).
Dhanpat Jain, MD
Professor of Pathology and of Medicine
Yale School of Medicine
Director, Program in Gastrointestinal and Liver Pathology
Director, Fellowship in Gastrointestinal and Liver Pathology
New Haven, CT
Dr. Dhanpat Jain is a Professor of Pathology and Internal Medicine (section of Digestive Diseases). He is also the director of the program in gastrointestinal pathology at Yale. Dr. Jain graduated from Mysore Medical College, Mysore, India and received his M.B.B.S degree in 1986. He subsequently received his M.D. Pathology degree from Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India in 1991. He moved to the U.S. in 1995 and completed his Anatomic Pathology residency and Fellowship in Gastrointestinal Pathology at Yale University School of Medicine, and subsequently continued as a faculty there.
Dr. Jain is a nationally and internationally recognized gastrointestinal pathologist known for his diagnostic skills, research and teaching. He has more than 100 publications, many book chapters, books and reviews, all of which are largely in the field of gastrointestinal and liver pathology. He has delivered many lectures and participated in many courses at the national and international level. He is on the editorial board of several high impact journals in the field of gastrointestinal and liver disorders. His area of expertise is motility disorders of the gastrointestinal tract, for which he gets cases in consultation from across the globe. Dr. Jain is an accomplished teacher and has received many awards. He has continuously been nominated for “Best Doctors in America” for many years.
Cheng-Han Lee, MD, PhD, FRCPC
Clinical Assistant Professor
University of British Columbia
Medical Director, Department of Pathology & Laboratory Medicine
British Columbia Cancer Agency
Dr. Lee received his MD-PhD degree from the University of British Columbia (UBC) in 2004 and completed his Anatomic Pathology residency training (UBC) in 2009. His interest in cancer genetics led him to pursue research fellowships at Stanford University Medical Center and Brigham and Women’s Hospital, where he studied the genetic basis and biology of high-grade endometrial stromal sarcoma. His work led to the recognition of a new disease entity that was subsequently adopted in the 2014 WHO classification system for tumors of the female reproductive system. More recently, Dr. Lee has applied various next generation sequencing methods and high-throughput assays to gain clinically and diagnostically informative insights into epithelial/mesenchymal tumors of the uterus, including the most aggressive subtypes of uterine cancer such as dedifferentiated endometrial cancer, carcinosarcoma as well as a number of uterine sarcoma types.
Dr. Lee currently has over 100 peer-reviewed publications and a number of book chapters, and is the recipient of a number of young investigator/junior scientist awards from both national and international organizations. He is currently a consultant pathologist and the medical director of the department of Pathology and Laboratory Medicine at British Columbia Cancer Agency. His subspecialty practice interests are in gynecologic, bone/soft tissue and molecular pathology.
E. Celia Marginean, MD, FRCPC, FCAP
Professor of Pathology, University of Ottawa
Head, Gastrointestinal Pathology Section
Deputy Director Section of Cytopathology
The Ottawa Hospital
Dr. Marginean is a Full Professor of Pathology at Ottawa University.
She has a number of local, provincial and national leadership roles: Head of GI Pathology Section and Deputy Head of Cytopathology Section at Ottawa Hospital; She is part of several committees: Canadian Partnership Against Cancer , GI Endoscopy Steering Committee Champlain LHIN, Communities of Practice Champlain LHIN (thyroid, colorectal), US and Canadian Academy of Pathologists, Commonwealth Neuroendocrine Tumour Group.
She is the current president of Ontario Association of Pathologists.
The majority of her research projects are related to biomarkers in cancer, and were presented at local, national or international meetings and published in high impact peer-reviewed journals
Torsten O. Nielsen MD/PhD FRCPC
Professor of Pathology and Laboratory Medicine
Associate Member, Department of Orthopaedics
University of British Columbia
Chair, Sarcoma Disease Site Committee
Canadian Cancer Trials Group
Torsten O. Nielsen is a Professor of Pathology and Laboratory Medicine at the University of British Columbia. After completing the combined MD/PhD program at McGill, he undertook training at UBC, ICRF London, Stanford, the Cleveland Clinic and the Royal Orthopaedic before taking a position as a clinician-scientist pathologist, specializing in sarcomas. His contributions have included the world’s first large scale microarray studies of sarcomas, development of the DOG-1, TLE and beta-catenin biomarkers, identification of the biology driving tenosynovial giant cell tumors, synovial sarcoma and epithelioid sarcoma, and involvement in clinical trials of targeted therapies for these tumor types. Dr. Nielsen is co-chair of the Sarcoma Disease Site Committee for the Canadian Cancer Trials Group
Jeffrey S. Ross, MD
Jones-Rohner Professor of Pathology and Urology
Upstate Medical University
Foundation Medicine Inc.
Jeffrey S. Ross is a graduate of Oberlin College, Oberlin, Ohio and The State University of New York at Buffalo School of Medicine in Buffalo, New York. He trained in Pathology at the Massachusetts General Hospital in Boston, Massachusetts.
From 1977 until 1989 he was Professor and Assistant Dean University of Massachusetts Medical School and research Assistant Professor at Harvard Medical School and the Massachusetts General Hospital. Dr. Ross was the Cyrus Strong Merrill Professor and Chairman of the Department of Pathology and Laboratory Medicine at the Albany Medical College in Albany, New York from 1989 to 2017. In 2017, Dr. became the Jones-Rohner Endowed Professor of Pathology, Oncology and Urology at the Upstate Medical University in Syracuse, NY.
In 2009, Dr. Ross became the Founding Strategic Advisor and the Medical Director for Foundation Medicine, Inc. in Cambridge, MA. Dr. Ross has received numerous academic awards, six patents in molecular diagnostics and is the author of more than 900 peer-reviewed scientific articles and abstracts, 4 textbooks and numerous book chapters in the fields of pathology, molecular diagnostics, oncology and translational cancer research.
Stephen Yip MD, PhD, FRCPC
Neuropathologist, Vancouver General Hospital
Associate Professor of Medicine, University of British Columbia
Stephen Yip completed his MD-PhD training at UBC followed by 4/6 years of neurosurgery residency when he decided to switch to neuropathology. He did his fellowship training at the Massachusetts General Hospital under the mentorships of David Louis and John Iafrate. Stephen Yip is a contributor to the 2016 WHO Classification of CNS Tumours. In 2012, I discovered recurrent mutations in CIC in a majority of 1p19q-codeleted, IDH mutated oligodendroglioma. He is collaborating with Marco Marra in the Personalized OncoGenomics (POG) program of which he is the lead pathologist and is also branching out to large-scale epigenomics and proteomic investigations.